 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...1415161718192021222324...266267» |
- Opdivo (nivolumab) / BMS, SCIB1 / Scancell, Yervoy (ipilimumab) / BMS
A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial. (Hall A; Poster Bd #: 319) - Apr 24, 2024 - Abstract #ASCO2024ASCO_845;
P2
SCIB1 given with nivolumab and ipilimumab, as 1 st line treatment in unresectable melanoma, improved the ORR to 85% without an increase in clinically meaningful adverse events. These results, if confirmed in the larger ongoing patient cohort, provide confidence in initiating a randomized registration program in unresectable melanoma patients with this novel DNA plasmid technology.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Overall survival after isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM II trial). (Hall A; Poster Bd #: 317) - Apr 24, 2024 - Abstract #ASCO2024ASCO_843;
P3
One dose of IPI3/NIVO1 before IHP had no obvious benefit in response or OS, but was associated with higher rates of toxicity. There was no apparent survival advantage compared to patients in the SCANDIUM trial with IHP only, however, sample size and non-overlapping patient characteristics severely hamper comparison between the trials.
- Opdivo (nivolumab) / BMS
Continuous intrathecal infusion of nivolumab in advanced melanoma with leptomeningeal disease. (Hall A; Poster Bd #: 306) - Apr 24, 2024 - Abstract #ASCO2024ASCO_832;
However 3 patients had prolonged survival (>=1 year). Median nivolumab concentrations in CSF were comparable to through plasma concentrations at steady state after 3mg/kg IV infusion.
- Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma. (Hall A; Poster Bd #: 303) - Apr 24, 2024 - Abstract #ASCO2024ASCO_829;
P2
Longer follow-up is required for the accurate assessment of OS. No significant toxicity increases were observed with the addition of UV1.
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048. (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_821;
P1/2
There were no new safety signals with NIVO + RELA + IPI, and the safety profile was generally consistent with I-O combinations. Given the small sample size, additional studies are needed to confirm the efficacy and safety of NIVO + RELA + IPI.
- Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN). (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_820;
Given the small sample size, additional studies are needed to confirm the efficacy and safety of NIVO + RELA + IPI. The EBIN trial shows there is no difference in PFS between the two treatment arms for unselected patients but supports the hypothesis that patients with very high LDH and those with liver metastases benefit from the sequential approach.
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma. (Hall A; Poster Bd #: 503) - Apr 24, 2024 - Abstract #ASCO2024ASCO_784;
P1/2
The EBIN trial shows there is no difference in PFS between the two treatment arms for unselected patients but supports the hypothesis that patients with very high LDH and those with liver metastases benefit from the sequential approach. Taken together we have confirmed that (1) Trabectedin in combination with Ipilimumab and Nivolumab is a safe and effective regimen for previously untreated advanced STS, and (2) Randomized studies are needed to confirm whether this regimen is superior to standard first line therapy for advanced soft tissue sarcoma.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy. (Hall A; Poster Bd #: 495) - Apr 24, 2024 - Abstract #ASCO2024ASCO_777;
In this large analysis, KS, ASPS, AS, MFS, and UPS demonstrated the best ORR and longest PFS while OS, SS, and LPS were the lowest. TMB ?10 and PD-L1 expression also correlated with increased ORR.
- || Voyager-V1 / Vyriad
Trial primary completion date, Combination therapy: Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients (clinicaltrials.gov) - Apr 24, 2024
P2, N=87, Recruiting, Sponsor: Vyriad, Inc.
TMB ?10 and PD-L1 expression also correlated with increased ORR. Trial primary completion date: Mar 2024 --> Dec 2024
- | VAC85135 / J&J
Trial completion date: A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms (clinicaltrials.gov) - Apr 24, 2024
P1, N=60, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Mar 2024 --> Dec 2024 Trial completion date: Jul 2028 --> Nov 2027
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Journal, Metastases: Predictive factors of nivolumab plus ipilimumab treatment efficacy in metastatic renal cell carcinoma patients. (Pubmed Central) - Apr 23, 2024
The presence of paraneoplastic symptoms was an independent predictor of progression-free survival. Improvement in paraneoplastic symptoms may reflect the treatment efficacy of nivolumab plus ipilimumab.
- || Voyager-V1 / Vyriad
Trial completion date, Trial primary completion date, Checkpoint inhibition: Ph I/II Trial of Systemic VSV-IFN?-NIS in Combination with Checkpoint Inhibitor Therapy in Patients with Select Solid Tumors (clinicaltrials.gov) - Apr 23, 2024
P1/2, N=70, Recruiting, Sponsor: Vyriad, Inc.
Improvement in paraneoplastic symptoms may reflect the treatment efficacy of nivolumab plus ipilimumab. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date, Trial primary completion date: CHINOREC: Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer (clinicaltrials.gov) - Apr 23, 2024
P2, N=80, Completed, Sponsor: Johannes Laengle, MD, PhD
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2024 | Trial primary completion date: Jun 2024 --> Mar 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial: A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma (clinicaltrials.gov) - Apr 22, 2024
P1, N=12, Not yet recruiting, Sponsor: University Health Network, Toronto
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
P1 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal, Checkpoint inhibition, Tumor-specific neoantigens, PD(L)-1 Biomarker, IO biomarker, Checkpoint block, Metastases: A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. (Pubmed Central) - Apr 22, 2024
P1/2
These data led to the development of an optimized vaccine exclusively targeting KRAS-derived neoantigens that is being evaluated in a subset of patients in phase 2 of the clinical study. ClinicalTrials.gov registration: NCT03953235 .
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Real-world evidence, Real-world: Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma. (Pubmed Central) - Apr 22, 2024
Patients discontinuing therapy prematurely, for other reasons than recurrence, had similar outcomes as patients finalizing planned treatment. First-line metastatic treatment with ipilimumab and nivolumab post-adjuvant anti-PD-1 did not show improved outcomes compared to ipilimumab/anti-PD-1 monotherapy.
- || UV1 / Ultimovacs, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
P2 data, Journal: UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial. (Pubmed Central) - Apr 22, 2024
The primary endpoint was not met. Predefined analyses of response rates are in favour of adding the vaccine.
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: Understanding and overcoming resistance to immunotherapy in genitourinary cancers. (Pubmed Central) - Apr 21, 2024
Currently, several targeted agents are in development, along with the identification of key immune mediators involved in immunotherapy resistance. Further research is necessary to identify predictors of response.
- Modi-1 / Scancell, SCIB1 / Scancell
Clinical Update on the DC Targeting Melanoma Vaccine, SCIB1 and The Modi-1 Vaccine Targeting Citrullination () - Apr 19, 2024 - Abstract #IOSUMMITEUROPE2024IO_SUMMIT_EUROPE_60;
Citrullination occurs in stressed tumor cells and makes an excellent target for a universal cancer vaccine. Modi-1 targeting citrullination is currently in phase II clinical trial
- | Enrollment open: CARE1 Pragmatic Clinical Trial (clinicaltrials.gov) - Apr 18, 2024
P3, N=1250, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Modi-1 targeting citrullination is currently in phase II clinical trial Not yet recruiting --> Recruiting
- | Trial completion date, Trial primary completion date: DREAMseq: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (clinicaltrials.gov) - Apr 18, 2024
P3, N=300, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
- | Yondelis (trabectedin) / PharmaMar, J&J, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, IO biomarker: SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Apr 18, 2024
P1/2, N=45, Recruiting, Sponsor: Sarcoma Oncology Research Center, LLC
Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024 Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- ||| UV1 / Ultimovacs
Trial completion, Trial completion date, Trial primary completion date: INITIUM: UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma (clinicaltrials.gov) - Apr 18, 2024
P2, N=156, Completed, Sponsor: Ultimovacs ASA
Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Apr 2024 | Trial primary completion date: Apr 2024 --> Jan 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: C-IT Neo: CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma (clinicaltrials.gov) - Apr 17, 2024
P2, N=28, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Apr 2024 | Trial primary completion date: Apr 2024 --> Jan 2024 Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
- | Trial completion date, Trial primary completion date: Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Apr 16, 2024
P1, N=20, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date, Trial primary completion date: INSPIRE: Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (clinicaltrials.gov) - Apr 16, 2024
P2, N=69, Active, not recruiting, Sponsor: Radboud University Medical Center
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Feb 2026 | Trial primary completion date: Jan 2025 --> Aug 2024
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
P1 data, Journal: Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. (Pubmed Central) - Apr 15, 2024
P1
administration of dual ICB is safe and demonstrated durable responses in a subset of patients with advanced gynecologic malignancy. The RP2D is 3
- | Cyramza (ramucirumab) / Eli Lilly
Clinical Trial,Phase II, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases: Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy. (Pubmed Central) - Apr 15, 2024
Medical records of patients with aGEC enrolled in the randomized phase II AIO-STO-0417 trial after treatment failure to first-line FOLFOX plus nivolumab and ipilimumab were retrospectively analyzed...Patients with CPS ?1 in the RAM group showed better tumor control (ORR 25% vs 10%) and improved survival (total OS 11.5 vs 8.0?months; second-line OS 6.5 vs 3.9?months; PFS 4.5 vs 1.6?months) compared to the control. Prior exposure to first-line FOLFOX plus dual checkpoint inhibition followed by RAM plus chemotherapy shows favorable response and survival rates especially in patients with initial response and positive PD-L1 expression and has the potential to advance the treatment paradigm in aGEC.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial: NeoRelapse: Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma (clinicaltrials.gov) - Apr 15, 2024
P2, N=25, Not yet recruiting, Sponsor: University of Utah
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, Checkpoint inhibition: DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC (clinicaltrials.gov) - Apr 15, 2024
P2, N=24, Not yet recruiting, Sponsor: University of Alabama at Birmingham
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date, Trial primary completion date, Metastases: CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Apr 15, 2024
P2, N=16, Completed, Sponsor: M.D. Anderson Cancer Center
Prior exposure to first-line FOLFOX plus dual checkpoint inhibition followed by RAM plus chemotherapy shows favorable response and survival rates especially in patients with initial response and positive PD-L1 expression and has the potential to advance the treatment paradigm in aGEC. Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Apr 2024 | Trial primary completion date: Jan 2025 --> Apr 2024
- | New P3 trial: CARE1 Pragmatic Clinical Trial (clinicaltrials.gov) - Apr 14, 2024
P3, N=1250, Not yet recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- || Imfinzi (durvalumab) / AstraZeneca, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical data, Journal, Metastases: Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab. (Pubmed Central) - Apr 13, 2024
Grade 3 adverse events, including pneumonitis, dermatitis, and colitis, occurred in 10% of the patients. This study suggests that nivolumab plus ipilimumab is effective, especially in patients who have received durvalumab for 6 months or more, and tolerable for patients who relapsed after durvalumab following CCRT.
- | Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Early Serum Markers for Immune Checkpoint Inhibitor Induced Hypophysitis in Melanoma Patients. (Pubmed Central) - Apr 13, 2024
Whereas a drop in T4 levels was indicative of developing hypophysitis independent of the ICI regime, TSH levels only declined in patients under ipilimumab-based ICI regimes. To best monitor our patients, it is important to recognize these differences.
- || Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal, Metastases: Neo-Adjuvant Therapy for Metastatic Melanoma. (Pubmed Central) - Apr 13, 2024
P3
The community is keen to see the first results (expected in 2024) of the phase 3 NADINA trial (NCT04949113), which randomized patients between surgery + adjuvant anti-PD-1 and two NAS therapy courses of a combination of ipilimumab + nivolumab, followed by surgery and a response-driven adjuvant regimen or follow-up. We are on the eve of neo-adjuvant systemic (NAS) therapy, particularly immunotherapy, becoming the novel standard of care for macroscopic stage III melanoma.
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Immunotherapy and Cannabis: A Harmful Drug Interaction or Reefer Madness? (Pubmed Central) - Apr 13, 2024
Although it is mechanistically plausible that cannabis could have immunosuppressive effects which inhibit the response to immunotherapy, these two reports should be viewed cautiously. Larger prospective studies of this purported drug interaction that account for potential confounds (e.g., greater nicotine smoking among cannabis users) may be warranted.
- ||| Journal, Adverse events: Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience. (Pubmed Central) - Apr 12, 2024
PD-L1/PD-1 inhibitors frequently caused various irAEs but their severities were mostly tolerable. Few patients developed delayed irAE with mild toxities.
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Review, Clinical Trial,Phase II, Journal, Checkpoint inhibition: Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management. (Pubmed Central) - Apr 12, 2024
Here, we described the case of a 55-year man with metastatic melanoma, facing a brutal right peripheral cerebral palsy after his third ipilimumab/nivolumab infusion. After the case presentation, we reviewed the literature about this rare complication of immunotherapy, and described its diagnosis work-up and clinical management.
- | Prolia (denosumab) / Amgen, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion: A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV Melanoma (EUDRACT) - Apr 12, 2024
P1/2, N=72, Completed, Sponsor: Peter MacCallum Cancer Centre
After the case presentation, we reviewed the literature about this rare complication of immunotherapy, and described its diagnosis work-up and clinical management. Active, not recruiting --> Completed
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion: NCI-2018-03329: Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer (clinicaltrials.gov) - Apr 11, 2024
P1, N=7, Completed, Sponsor: Claire Verschraegen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| alintegimod (7HP349) / 7 Hills Pharma
New P1/2 trial, Monotherapy: A Study of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy (clinicaltrials.gov) - Apr 11, 2024
P1/2, N=126, Not yet recruiting, Sponsor: 7 Hills Pharma, LLC
- || Keytruda (pembrolizumab) / Merck (MSD)
Review, Journal: When Hormones are Being Difficult: A Rare Case and the Literature Review of Pembrolizumab-Induced Polyendocrinopathy. (Pubmed Central) - Apr 10, 2024
The patient was started on hydrocortisone therapy with improvement in symptoms...Only a few cases of pembrolizumab-induced polyendocrinopathy have been reported so far which we have mentioned in this article. While patients are on immunotherapy, close monitoring for clinical signs & symptoms can lead to an early diagnosis, substantially improving morbidity and mortality.
- || Review, Journal: Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party. (Pubmed Central) - Apr 10, 2024
Currently, seven ICIs, namely ipilimumab (anti-cytotoxic T lymphocyte-associated protein 4 [CTLA4]), pembrolizumab, nivolumab (anti-programmed cell death protein 1 [PD-1]), atezolizumab, avelumab, durvalumab, and cemiplimab (anti-PD-L1), have been approved for various cancer types. Consequently, ongoing studies are evaluating the next generation of ICIs, such as lymphocyte activation gene-3 (LAG3), T
- ||| Retrospective data, Review, Journal, Adverse events, Checkpoint inhibition, Metastases: Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis. (Pubmed Central) - Apr 10, 2024
The analysis focused on the probability of irAEs occurrence in each system when mRCC patients were treated with different ICI-based therapies, potentially offering significant value for guiding clinical prevention, early diagnosis, and management of irAEs. The limitations of the study included the potential heterogeneity and low certainty of part of the evidence.
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: CheckMate 901: Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer (clinicaltrials.gov) - Apr 10, 2024
P3, N=1290, Active, not recruiting, Sponsor: Bristol-Myers Squibb
The limitations of the study included the potential heterogeneity and low certainty of part of the evidence. Trial primary completion date: Apr 2024 --> Oct 2024
- ||| Opdivo (nivolumab) / BMS
Enrollment change, Trial completion date, Trial primary completion date: CA209-8TT: Pan Tumor Rollover Study (clinicaltrials.gov) - Apr 10, 2024
P2, N=1500, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Apr 2024 --> Oct 2024 N=800 --> 1500 | Trial completion date: Aug 2025 --> Aug 2029 | Trial primary completion date: Aug 2025 --> Aug 2029
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition: Successful treatment of immune checkpoint inhibitor-related periaortitis. (Pubmed Central) - Apr 9, 2024
Immune checkpoint inhibitors were discontinued, and the patient was treated with glucocorticoids, leading to a complete resolution of the periaortitis. To our knowledge, this is only the third reported case of immune checkpoint inhibitor-related periaortitis.
- Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / Ono Pharma, BMS
Development of a predictive administrative claims () - Apr 9, 2024 - Abstract #AMCP2024AMCP_38;
To our knowledge, this is only the third reported case of immune checkpoint inhibitor-related periaortitis. The presence of the following claims during the follow-up period were selected in the final decision tree as predictors:
- | CRS-207 / Novartis, Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 8, 2024
P2, N=17, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The presence of the following claims during the follow-up period were selected in the final decision tree as predictors: Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Dec 2024 --> Apr 2024
- ||| XH001 / NeoCura, Yervoy (ipilimumab) / BMS
New trial: XH001 Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer (clinicaltrials.gov) - Apr 8, 2024
P=N/A, N=12, Not yet recruiting, Sponsor: Wu Wenming